Crinecerfont
- Generic Name
- Crinecerfont
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H28ClFN2OS
- CAS Number
- 752253-39-7
- Unique Ingredient Identifier
- MFT24BX55I
- Associated Conditions
- -
- Associated Therapies
- -
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 103
- Registration Number
- NCT04806451
- Locations
- 🇬🇧
Neurocrine Clinical Site, London, United Kingdom
🇺🇸Neurocrine Clinical site, Saint Louis, Missouri, United States
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 182
- Registration Number
- NCT04490915
- Locations
- 🇬🇧
Neurocrine Clinical Site, Salford, United Kingdom
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 8
- Registration Number
- NCT04045145
- Locations
- 🇺🇸
Neurocrine Clinical Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath